ALK+ NSCLC Archives - Patient Worthy

Photo by Robina Weermeijer on Unsplash

Rare Community Profiles: A Potential Treatment Turning Point for ALK-Positive NSCLC: Dr. Ken Culver Shares Insights from the Phase 3 ALINA Study on Alecensa

Post author:Jessica Lynn
Post published:March 27, 2024
Post category:Lung Cancer Rare Disease

Rare Community Profiles is a Patient Worthy article series of long-form interviews featuring various stakeholders in the rare disease community, such as patients, their families, advocates, scientists, and more.…

source: pixabay.com

Real-World Data on Brigatinib as a Treatment for ALK+ Non-Small Cell Lung Cancer

Post author:Kendall Mason
Post published:June 1, 2021
Post category:Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer

Brigatinib has been approved for the treatment of ALK+ metastatic non-small cell lung cancer (NSCLC), as well as ALK+ NSCLC patients who have received prior treatment with crizotinib. While it…

Takeda’s Alunbrig Web Event

Post author:James Moore
Post published:June 9, 2020
Post category:

Speakers: Viola Zhu, MD, PhD, University of California Irvine & Larissa, Patient Ambassador Join us to learn more about ALK+ non-small cell lung cancer (NSCLC) and ALUNBRIG (brigatinib) as a…

Takeda’s Alunbrig Web Event

Post author:James Moore
Post published:May 13, 2020
Post category:

Speakers: Tarek Mekhail, MD, Advent Health Cancer Institute & Larissa, Patient Ambassador Join us to learn more about ALK+ non-small cell lung cancer (NSCLC) and ALUNBRIG (brigatinib) as a treatment…

Takeda’s Alunbrig Web Event

Post author:James Moore
Post published:April 28, 2020
Post category:

Speakers: Shayma Kazmi, MD, RPh Cancer Treatment Center of America & Danielle, Patient Ambassador Join us to learn more about ALK+ non-small cell lung cancer (NSCLC) and ALUNBRIG (brigatinib) as…

kalhh / Pixabay

ALUNBRIG Approved by European Commission as Treatment for Patients with ALK+ NSCLC

Post author:Jessica Lynn
Post published:April 10, 2020
Post category:Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer

According to a release on Biospace, the European Commission (EC) has approved Takeda Pharmaceutical's ALUNBRIG (brigatinib) as treatment for patients with anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer…

Takeda’s Alunbrig Web Event

Post author:James Moore
Post published:March 19, 2020
Post category:

Speakers: Jason A. Salganick, MD & Larissa C., Patient Ambassador Join us to learn more about ALK+ non-small cell lung cancer (NSCLC) and ALUNBRIG (brigatinib) as a treatment option for…

source: pixabay.com

How an ALK+ Non-Small Cell Lung Cancer Patient Became an Advocate

Post author:Kendall Mason
Post published:March 12, 2020
Post category:Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer

Gina Hollenbeck never considered that she could have lung cancer. She did not fall into any categories that would put her at a higher risk of cancer; she didn't smoke,…

Rare Community Profiles: A Potential Treatment Turning Point for ALK-Positive NSCLC: Dr. Ken Culver Shares Insights from the Phase 3 ALINA Study on Alecensa

Real-World Data on Brigatinib as a Treatment for ALK+ Non-Small Cell Lung Cancer

Takeda’s Alunbrig Web Event

Takeda’s Alunbrig Web Event

Takeda’s Alunbrig Web Event

ALUNBRIG Approved by European Commission as Treatment for Patients with ALK+ NSCLC

Takeda’s Alunbrig Web Event

How an ALK+ Non-Small Cell Lung Cancer Patient Became an Advocate

The Let’s Chat CAR T One-on-One Mentor Program: Speaking with Someone Who Understands What You Are Going Through

“Shades of Psoriasis”: Plaque Psoriasis and Sharing Your Story

Understanding RSV: Why Combatting Ethnic and Age-Related Health Disparities Could Improve Outcomes

We Need Equity and Diversity Within Rare Disease Research

DNA in Color: How Ronya Nelson is Working to Close the Diversity Gap in Genetics - Part 1

Bridging the Diversity Gap in Healthcare

Congratulations to the 2023 Recipients of the Diversity in Lupus Research Awards!

Welcome to Study of the Week. We go in-depth and select a study we think is of particular interest, discussing details, explaining its importance, who may be impacted and lots more!

Let’s Work Together!

Keep Up to Date

Learn More